Has Barry Horowitz, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,072,790 in general payments to Barry Horowitz, MD across 2,076 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Barry Horowitz, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Barry Horowitz, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Barry Horowitz, MD

Endocrinology, Diabetes & Metabolism · West Palm Beach, FLNPI 1437163003

Payments from drug & device makers

$7,072,790in general payments, 2019–2025

Across 2,076 payments — averaging $3406.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eli Lilly$2.7M
Incyte Corporation$1.6M
AbbVie$766K
Abbott$522K
Lilly USA, LLC$423K
Medtronic$304K
plus $786K from 54 others

$29,595in research payments, 2019–2025

Across 14 payments — averaging $2113.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$30K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eli Lilly	82	$2,710,981
Incyte Corporation	237	$1,560,803
AbbVie(2 entities)	122	$766,006
Abbott	54	$522,187
Lilly USA, LLC	675	$422,993
Medtronic(2 entities)	45	$304,046
GSK	61	$206,381
BD	6	$197,308
Novo Nordisk	225	$107,457
Insulet Corporation	37	$82,910
Bristol Myers Squibb	3	$57,087
Dexcom, Inc.	10	$38,697
AstraZeneca(2 entities)	73	$36,101
Johnson & Johnson	22	$15,953
Sanofi US Services Inc.	7	$8,295
Esperion Therapeutics, Inc.	7	$6,928
Ionis Pharmaceuticals, Inc.	4	$5,373
Merck	16	$4,909
Tandem Diabetes Care, Inc.	6	$3,186
Vivus LLC	8	$2,213
Lexicon Pharmaceuticals, Inc.	1	$2,000
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	5	$1,588
Amgen(2 entities)	59	$1,452
Tosoh Bioscience, Inc.	2	$1,078
Bayer	41	$1,025
Mannkind Corporation	30	$852
Boehringer Ingelheim	29	$604
Sanofi-aventis U.S. LLC	21	$572
Novartis	21	$471
Xeris Pharmaceuticals, Inc.	30	$436
Antares Pharma, Inc.	20	$317
Radius Health, Inc.	15	$264
Sequel Med Tech, LLC	6	$246
Neurocrine Biosciences, Inc.	5	$216
Amneal Pharmaceuticals LLC	14	$201
Amarin Pharma, Inc.	12	$187
BETA Bionics, Inc.	1	$146
Ipsen Biopharmaceuticals, Inc	3	$144
Madrigal Pharmaceuticals	4	$123
Corcept Therapeutics	6	$117
Lifescan, Inc.	7	$111
Alvogen Inc	3	$62
Sanofi Pasteur Inc.	3	$59
Recordati_rare_diseases_inc.	3	$53
Halozyme Inc	3	$49
Ascendis Pharma Endocrinology Inc	2	$43
Vanda Pharmaceuticals Inc.	2	$41
Nevro Corp.	2	$40
Pfizer	2	$40
Verity Pharmaceuticals Inc.	2	$37
Shire North American Group Inc	2	$36
Takeda Pharmaceuticals U.S.A., Inc.	2	$34
Globus Medical	1	$33
Quidel Corporation	1	$32
Cequr Corporation	2	$32
Regeneron Healthcare Solutions, Inc.	1	$31
Acerus Pharmaceuticals Corporation	2	$27
Ultragenyx Pharmaceutical Inc.	1	$22
Astellas Pharma US Inc	1	$22
Averitas Pharma Inc.	1	$21

How this compares

$7,072,790 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.

See all endocrinology, diabetes & metabolism providers in Florida →

Medicare billing

Part B allowed, 2024

$927,049

Medicare patients

1,043

Services billed

40,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in West Palm Beach

William KayeWest Palm Beach$1.3M
Richard PratleyOrlando$9.2M
Jose MandryOcoee$9.1M
Steven SmithOrlando$7.9M
Tina ThethiOrlando$3.8M
David SuttonJacksonville$3.1M
Lorena Lewy-AlterbaumHollywood$3.1M
Mae Sheikh AliJacksonville$2.9M
James MageeJacksonville$2.7M
Rodolfo GalindoMiami$2.5M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →